Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2008
05/15/2008WO2008055870A1 Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
05/15/2008WO2008055854A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
05/15/2008WO2008055847A1 Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
05/15/2008WO2008055842A1 Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
05/15/2008WO2008055840A1 Thiazole and oxazole-substituted arylamides
05/15/2008WO2008055808A1 Indole and benzofuran 2-carboxamide derivatives
05/15/2008WO2008055710A1 Indole and indazole derivatives as anti-inflammatory agents
05/15/2008WO2008055709A1 Indazole and indole derivatives as anti -inflammatory agents
05/15/2008WO2008055669A1 Salt of aliskiren with orotic acid
05/15/2008WO2008055666A1 Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
05/15/2008WO2008055651A1 Improved biological effects of compositions comprising rosmarinic acid
05/15/2008WO2008055629A1 Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
05/15/2008WO2008055530A1 Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases
05/15/2008WO2008055445A1 Method and composition for increasing insulin sensitivity
05/15/2008WO2008055386A1 A water-soluble pharmaceutical composition for injection of 17-allyl amino-17-demethoxy geldanamycin
05/15/2008WO2008055361A1 E3 UBIQUITM LIGASE MKRNL AS A MARKER FOR MAMMALIAN STEM CELL PLUπPOTENCY AND METHODS AND USES THEREOF
05/15/2008WO2008055348A1 Reduced-hangover alcoholic beverage comprising turmeric
05/15/2008WO2008055317A1 Compositions and methods for the treatment of prostate cancer
05/15/2008WO2008039420A3 Novel inhibitors of beta-lactamase
05/15/2008WO2008038305A3 Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger.
05/15/2008WO2008038303A3 Therapeutic formulation comprising a sulfonylurea, a thiazolidinedione and a nitric oxide scavenger.
05/15/2008WO2008038030A3 Dispiro tetraoxane compounds and their use in the treatment of malaria and/or cancer
05/15/2008WO2008037681A8 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.
05/15/2008WO2008037045A3 Composition containing a mixture of antidepressants for treating premature ejaculation.
05/15/2008WO2008036843A3 Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
05/15/2008WO2008035359A3 Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
05/15/2008WO2008035358A3 Process for preparing dapoxetine
05/15/2008WO2008034866A3 Dbait and uses thereof
05/15/2008WO2008033798A3 A pyrrolopyrazin as syk-kinase inhibitor
05/15/2008WO2008033464A3 Azetidinone derivatives for the treatment of disorders of the lipid metabolism
05/15/2008WO2008032324A3 Combination therapy for tumoral disease treatment
05/15/2008WO2008031820A3 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
05/15/2008WO2008030949A3 Stable polyunsaturated fatty acid emulsions and methods for inhibitintg, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
05/15/2008WO2008030567A3 Dry powder compound formulations and uses thereof
05/15/2008WO2008029306A3 Thiophene derivatives as s1p1/edg1 receptor agonists
05/15/2008WO2008028928A8 Novel combination of agents for the treatment of hiv-associated adipose redistribution syndrome (hars)
05/15/2008WO2008027522A3 Solid composites of a calicum receptor-active compound
05/15/2008WO2008025790A3 Use of opioid formulations in needle-less drug delivery devices
05/15/2008WO2008024492A3 Indolinone phenylaminopropanol derivatives and process for the preparation thereof
05/15/2008WO2008022032A3 Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same
05/15/2008WO2008021339A3 Pyrrolidine and related derivatives useful as pr modulators
05/15/2008WO2008015695A3 Inclusion complex of olopatadine and cyclodextrin
05/15/2008WO2008015538A3 Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine
05/15/2008WO2008012227A3 Pyrazoles as glucokinase activators
05/15/2008WO2008011487A3 L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
05/15/2008WO2008008660B1 Cyclopentane derivatives as antiglaucoma agents
05/15/2008WO2008008310A3 Tyrosine kinase inhibitors
05/15/2008WO2008006969A3 Novel tetracyclic derivatives, process for the preparation thereof and pharmaceutical compositions which contain them
05/15/2008WO2008005806A3 Therapeutic methods, compositions, and compounds
05/15/2008WO2008001389A3 Female contraceptive for transcervical delivery and its' preparation
05/15/2008WO2008001311A3 Pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate
05/15/2008WO2008001278A3 Extracts of plectranthus hadiensis, argenatus or myrianthus for the treatment of microbial infection
05/15/2008WO2007147372B1 Pharmaceutical composition for administration by injection
05/15/2008WO2007146417A3 Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity
05/15/2008WO2007138112A3 Compounds that interact with ion channels, in particular with ion channels from the kv family
05/15/2008WO2007130825A3 Fused heterocyclic compounds and their use as mglur5 modulators
05/15/2008WO2007121312A3 Trivalent chromium compounds, compositions and methods of use
05/15/2008WO2007107787A3 Liquid and solid dosage formulations containing date fruit (phoenix dactylifera)
05/15/2008WO2007103447A8 A method for the preparation of recombinant human thrombin
05/15/2008WO2007092414A3 Use of phosphatases to treat tumors overexpressing n-cor
05/15/2008WO2007089659A3 Tat-039 and methods of assessing and treating cancer
05/15/2008WO2007084765A3 Injectable combination therapy for eye disorders
05/15/2008WO2007076351A3 Rnai-mediated inhibition of hif1a for treatment of ocular angiogenesis
05/15/2008WO2007073479A3 Radiotherapeutic high specific activity tin-117m and methods of use
05/15/2008WO2007062028A8 Treatment of qt interval prolongation and diseases associated therewith
05/15/2008WO2007052104A8 Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
05/15/2008WO2007050866A8 Oligodendrocyte-myelin glycoprotein compositions and methods of use thereof
05/15/2008WO2007034254A8 Amino-alkyl-amide derivatives as ccr3 receptor ligands
05/15/2008WO2007018941A3 Pyrimidyl-thiophene derivatives
05/15/2008WO2005102378A3 Modular furniture system
05/15/2008WO2005086954A3 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
05/15/2008US20080115242 Genetically Modified Plant Producing Lactosyl Ceramide and Utilization of the Same
05/15/2008US20080114285 Energy-activated targeted cancer therapy
05/15/2008US20080114281 Transdermal Delivery System for Polynucleotides
05/15/2008US20080114187 Formoterol tartrate process and polymorph
05/15/2008US20080114165 Methods for the Preparation of {2-[(8,9)-Dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} Phosphonic Acid and Esters Thereof
05/15/2008US20080114075 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, or sultosilic acid for example; combination therapy with other drugs
05/15/2008US20080114074 Phytoene and/or phytofluene
05/15/2008US20080114073 2,4,6,-Trisubstituted phenols having anesthetic properties
05/15/2008US20080114072 N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof
05/15/2008US20080114071 Processes for preparing sertraline
05/15/2008US20080114070 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
05/15/2008US20080114069 Methods of inducing terminal differentiation
05/15/2008US20080114068 HIV antiviral agents; 2-((p-carboxyphenyl)aminocarbonylmethoxy)-5-halo-benzophenone compounds
05/15/2008US20080114067 Comprising as active ingredients amino acid selected from tyrosine, methionine, phenylalanine and glutamine together with a branched chain amino acid of L-valine, L-leucine or L-isoleucine; dosage; health drink
05/15/2008US20080114066 Synergistic Effects Of Docosahexaenoic Acid (DHA) And Carotenoid Absorption Of Cognitive Function
05/15/2008US20080114065 Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium; preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation
05/15/2008US20080114064 Tri(Hydroxymethyl)Methylamine Salt or an Ethanol Amine Salt of (2S)-2-Ethoxy-3-(4-PHENYL) Propanoic Acid
05/15/2008US20080114063 Calcium dobesilate for example; benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis; combination therapy
05/15/2008US20080114062 N-(2-hydroxy-1-methyl-ethyl)-3-iodobenzamide; for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors; modulates cannabinoid receptors
05/15/2008US20080114061 Diphenylethylene compounds and uses thereof
05/15/2008US20080114060 Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Skin Cancer
05/15/2008US20080114059 Novel Compounds For Treatment of Cardiac Arrhythmia and Methods of Use
05/15/2008US20080114058 Use Of Lignan Compounds For Treating Or Preventing Inflammatory Disease
05/15/2008US20080114057 For therapy of dermatitis conditions and skin impairments such as atopic dermatitis, contact dermatitis, allergic contact dermatitis, allergic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of hands or feet, generalized exfoliative dermatitis, stasis dermatitis
05/15/2008US20080114056 Analgesics; e.g. osteoarthritis, cancer pain, myofascial pain (muscular injury, fibromyalgia) and perioperative pain, inflammatory pain; 7-(hydroxy, ether, ester, amide, or carbamate)-3-(substituted phenyl)-chromen-4-ones; chemical synthesis
05/15/2008US20080114055 By using [3-(3,4-Dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethyl-ammonium chloride to reduce or reverse cachexia or disease-induced body weight loss
05/15/2008US20080114054 Compositions and methods for reducing antimicrobial resistance of microbes
05/15/2008US20080114053 Method for Producing Fluorinated Proline Derivative
05/15/2008US20080114052 Cyclic derivatives as modulators of chemokine receptor activity